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T he Advisory Committee on Immunization
Practices and several states are considering recommending annual influenza vaccination in groups beyond the currently recommended high-risk groups. This offers an opportunity that should not be missed: to conduct a nationwide study of the effectiveness of vaccinating schoolchildren against influenza as a means of reducing community transmission. Some public health officials speak of universal vaccination against influenza, meaning a recommendation for all age groups, but schoolchildren, aged 5 to 18 years, are a prime target as they are generally considered to be the most important source of community-wide transmission. Researchers also believe that the immune systems of children respond better to influenza vaccination than do those in the elderly at-risk population. To realize maximum benefit from a study of such effects, we must prospectively sort out the crucial features to be evaluated: effectiveness, benefits, risks, and costs.
Highly pathogenic avian influenza A (H5N1) and its potential to unleash a pandemic are recently in the news. Aside from reducing community-wide transmission of seasonal influenza, vaccinating schoolchildren against influenza and putting its evaluation into place would prepare us for an organized response to an influenza pandemic, whenever it occurs. Our predictions suggest that if limited doses of vaccine were available, as might be expected during a pandemic, vaccinating schoolchildren would be the most efficient approach to reducing overall numbers of influenza cases.
A combination of vaccinating schoolchildren and older adults would be most effective for reducing influenza deaths (1, 2) Results from influenza simulations that we have conducted indicate that vaccinating just 20% of the schoolchildren would do more in reducing overall mortality in adults over 65 years old than vaccinating 90% of the adults over 65 years of age (see chart, page 616, top). Even though schoolchildren and young adults have not been considered at high risk of dying of influenza, annual morbidity is still high, with illness attack rates in schoolchildren exceeding 10% most years. Thus, the benefits would not be limited to the older population.
Expanding annual influenza vaccination would give vaccine manufacturers the incentive of a guaranteed market so that they would be willing to increase production capacity and stabilize the influenza vaccine pipeline. This improves our preparedness for a pandemic strain.
Arguments against and hindrances to vaccinating schoolchildren against influenza need to be taken seriously. Despite the benefits, children already receive many vaccinations, and parents and children balk at the idea of yet another, especially if needed annually. However, even if coverage were incomplete, community-wide benefits could be obtained provided that vaccination rates were 50% or higher, not to mention the direct protection of the vaccinated children. Use of a nasally administered live-attenuated influenza vaccine (LAIV) (3) might be an alternative to the traditional shots with killed vaccine. Influenza 
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vaccination is generally safe, with mild local reactions, such as soreness at the injection site with the killed vaccine, or runny nose with the LAIV, and, especially in persons with no previous exposure to influenza virus antigen, mild systemic reactions such as myalgia, fever, and malaise (4). Guillain-Barré syndrome was associated with the 1976 swine influenza vaccine, but not proven in later vaccines (4, 5) . Numerous logistical uncertainties remain to be worked out. Who would pay for the additional immunizations? Would distribution be through schools or physicians' offices? Who would carry the liability protection for potential or alleged injury due to vaccination?
We are not starting on a blank page. Attempts have been made before to demonstrate the community-wide effectiveness of vaccinating schoolchildren against influenza. Just before the epidemic in 1968, Monto and colleagues vaccinated 85% of the school-age children in Tecumseh, Michigan, against influenza, which resulted in a 67% decrease in the influenza-like illness attack rate in Tecumseh compared with neighboring Adrian (6) . In an ongoing community vaccination study in Central Texas with LAIV, Glezen and colleagues are attempting to demonstrate that vaccinating schoolchildren reduces the incidence of influenza-like illness in adults (7) . Although these studies are rigorous, they each have only one or two comparison communities.
A larger-scale study with numerous comparison communities is needed. A study in several schools in the former Soviet Union used a nonspecific outcome as well, so the results are difficult to interpret (8) . A compelling example of the need to plan evaluation prospectively is provided by the Japanese national vaccination strategy, which, for over two decades until 1987, was targeted at schoolchildren precisely to reduce epidemic influenza. A retrospective reassessment suggesting that the Japanese strategy reduced excess deaths among elderly adults (9) is open to criticism because it is based on nonspecific mortality data over time. The time trends could result from factors not related to influenza vaccination. More recently, the province of Ontario, Canada, has been promoting widespread vaccination for all age groups. The analysis of the Ontario experience suffers from weaknesses similar to that of the Japanese. A recent review of 14 studies concluded that further evidence is needed of the indirect effects of influenza vaccination in children (10) . Although mathematical models of the population-level effects of vaccination offer useful guidance, they cannot replace data from an actual study.
So, what are essential aspects of a successful study? The primary goal has to be evaluating whether increased coverage in schoolchildren would reduce the overall influenza illness attack and death rates in the community as a whole. Comparisons should be made between places where expanded coverage was implemented and those where current recommendations remained in place (see chart, this page, bottom) (11) . Although we could propose simply vaccinating children in half the states in the first year, followed by the rest of the states the next, it is neither feasible nor desirable. More tractable units of coverage are school districts, communities, cities, counties, or individual states. Enough pairs of units must be included to ensure that the study has statistical power to detect and estimate an effect. The more units are included in the study, the smaller is the chance that any observed differences in influenza incidence would be due to chance. Also, to allow for the possibility that, one year, the vaccine might be mismatched to the circulating strains or that the influenza season is particularly mild, the study should be continued for two or more years. This would also allow progressive inclusion of more communities. Such a geographically staggered introduction would permit vaccine production to ramp up for the increased demand and would give time to monitor potential safety concerns.
A vital factor in the success of such a study is the accurate and consistent diagnosis of influenza. Currently, influenza incidence is measured using nonspecific case definitions, such as pneumonia and influenza-like illness. If virologic confirmation of a random sample of influenza-like cases is done, the proportion of confirmed influenza-positive cases can be used to estimate the proportion of the nonspecific influenza-like cases that were in fact truly influenza (12, 13) . The importance of virologic confirmation in obtaining accurate estimates is highlighted by the Texas study above in which the direct protective efficacy of LAIV was estimated to be 18% (95% CI: 11, 24) by using a nonspecific case definition, and 79% (95% CI: 51, 91) when surveillance cultures were included (13) .
Many people alive today remember the large mobilization in the 1950s for the polio vaccine trials. Two important differences are that a study of the effect of vaccinating schoolchildren against influenza would involve a licensed rather than an experimental vaccine and would measure the overall effects on reducing transmission, morbidity, and mortality, rather than just the direct protective effects.
We propose nationwide mobilization for a study of influenza vaccination. Similar to the polio vaccine study (14) , a large study of influenza vaccination will need to be conducted by a partnership of academia, government, and industry. Government could provide the public health access, guidance in operations, and policy, as well as some funding for the research. Industry could provide vaccine and guidance in safety evaluation. Academia could provide expertise in innovative design and central coordination of the study.
Vaccination of schoolchildren will be a massive effort if introduced nationwide. Why not plan for its proper evaluation now? 
